从清浊相干论治糖脂代谢病

张永; 张小波; 沈涛

doi:10.14148/j.issn.1672-0482.2023.0707

从清浊相干论治糖脂代谢病

doi: 10.14148/j.issn.1672-0482.2023.0707

成都中医药大学基础医学院，四川成都 610075

基金项目:

国家自然科学基金面上项目 81973743

四川省科技厅重点研发计划项目 22ZDYF0905

详细信息

作者简介:
张永，男，博士研究生, E-mail: 568958305@qq.com

通讯作者:
沈涛，男，教授，博士生导师, 主要从事治则治法与方剂的理论及运用的研究, E-mail: shentaotcm@aliyun.com

中图分类号: R242
计量
- 文章访问数: 255
- HTML全文浏览量: 26
- PDF下载量: 41
- 被引次数: 0
出版历程
- 收稿日期: 2023-06-28
- 网络出版日期: 2023-08-17
- 发布日期: 2023-08-10

Discussion on Treatment of Glucose and Lipid Metabolism Diseases from the Perspective of Mutual Interference of Clear and Turbid Qi

School of Basic Medicine, Chengdu University of Traditional Chinese Medicine, Chengdu 610075, China

摘要

摘要: 清浊相干是指清浊之气升降失调，清气不升，浊气不降，精微物质转输障碍，成为内生浊邪的病机概括。胆汁酸可以通过激活胆汁酸受体，调节机体的糖脂代谢和能量代谢，是肠道发挥调控糖脂代谢稳态枢纽的重要途径。肠道胆汁酸受体可能是清浊相干理论的生物学基础，清浊相干，内生浊邪是糖脂代谢病的中医病机关键，升清降浊法是中医防治糖脂代谢病的重要治法。在清浊相干理论的指导下，通过调节肠道胆汁酸受体治疗糖脂代谢病，对厘清清浊相干理论的现代生物学基础具有重要的价值，为中医药论治糖脂代谢病提供新的思路。
- 糖脂代谢病 /
- 肠道胆汁酸受体 /
- 清浊相干 /
- 升清降浊
Abstract: The mutual interference of clear and turbid qi refers to the imbalance between the rise and fall of clear qi and turbid qi: the failure of clear qi to rise and turbid qi to fall, and the obstruction of the transfer of fine substances, which become a summary of the pathogenesis of endogenous turbid pathogens. Bile acids can regulate the body's glucose and lipid metabolism and energy metabolism by activating bile acid receptors, which is an important way for the intestinal tract to regulate the homeostasis of glucose and lipid metabolism. It is proposed that the receptor of intestinal bile acid is the biological basis of the mutual interference of clear and turbid qi theory; the mutual interference of clear and turbid qi, as well as the endogenous turbid pathogens, are the key pathogenesis of glucose and lipid metabolism diseases in traditional Chinese medicine; and ascending clear qi and lowering turbid qi is an important treatment method in traditional Chinese medicine for the prevention and treatment of glucose and lipid metabolism diseases. Under the guidance of the mutual interference of clear and turbid qi theory, regulating the intestinal bile acid receptors to treat glucose and lipid metabolism diseases is of great value in clarifying the modern biological basis of the "mutual interference of clear and turbid qi" theory, and provides new ideas for TCM to treat glycolipid metabolic diseases.
- glycolipid metabolic disease /
- intestinal bile acid receptor /
- mutual interference of clear and turbid qi /
- ascending clear qi and reducing turbidity qi

HTML全文

图 1 糖脂代谢病中清浊相干与肠道胆汁酸受体联系示意图

Figure 1. Schematic diagram of the relationship between mutual interference of clear and turbid qi and intestinal bile acid receptors in glucolipid metabolism diseases

下载: 全尺寸图片幻灯片

参考文献(64)

[1]	世界中医药学会联合会. 国际中医临床实践指南糖脂代谢病(2021-10-14)[J]. 世界中医药, 2021, 16(22): 3278-3284. doi: 10.3969/j.issn.1673-7202.2021.22.003 World Federation of Chinese Medicine Societies. International clinical practice guideline of Chinese medicine glucolipid metabolic disorders (2021-10-14)[J]. World Chin Med, 2021, 16(22): 3278-3284. doi: 10.3969/j.issn.1673-7202.2021.22.003
[2]	国家卫生和计划生育委员会疾病预防控制局. 中国居民营养与慢性病状况报告(2020年)[J]. 营养学报, 2020, 42(6): 521. https://www.cnki.com.cn/Article/CJFDTOTAL-CZSJ202114035.htm Disease Prevention and Control Bureau of the National Health and Family Planning Commission. Report on nutrition and chronic diseases of residents in China (2020)[J]. Acta Nutr Sin, 2020, 42(6): 521. https://www.cnki.com.cn/Article/CJFDTOTAL-CZSJ202114035.htm
[3]	PERINO A, SCHOONJANS K. Metabolic Messengers: Bile acids[J]. Nat Metab, 2022, 4(4): 416-423. doi: 10.1038/s42255-022-00559-z
[4]	李敏谦, 林育, 项磊, 等. 瘅浊与糖脂代谢病[J]. 世界中医药, 2019, 14(3): 652-655. doi: 10.3969/j.issn.1673-7202.2019.03.025 LI MQ, LIN Y, XIANG L, et al. Dan-Zhuo and glucolipid metabolic disorders[J]. World Chin Med, 2019, 14(3): 652-655. doi: 10.3969/j.issn.1673-7202.2019.03.025
[5]	李明珠, 陈谦峰, 陶文娟, 等. 基于"膏脂"生理特点与病理变化探析慢性代谢性疾病的防治[J]. 中医杂志, 2022, 63(4): 307-311. https://www.cnki.com.cn/Article/CJFDTOTAL-ZZYZ202204002.htm LI MZ, CHEN QF, TAO WJ, et al. Prevention and treatment of chronic metabolic diseases based on the physiological characteristics and pathological changes of "lipids"[J]. J Tradit Chin Med, 2022, 63(4): 307-311. https://www.cnki.com.cn/Article/CJFDTOTAL-ZZYZ202204002.htm
[6]	陈怡宁. 樊瑞红主任升清降浊法治疗原发性高脂血症经验[J]. 光明中医, 2022, 37(6): 974-976. doi: 10.3969/j.issn.1003-8914.2022.06.019 CHEN YN. Experience of director Fan Ruihong in treating primary hyperlipidemia with ascending the clear and descending the turbid method[J]. Guangming J Chin Med, 2022, 37(6): 974-976. doi: 10.3969/j.issn.1003-8914.2022.06.019
[7]	王志强, 庞国明, 王凯锋, 等. 庞国明教授"和法"治疗糖尿病的学术观点[J]. 世界中西医结合杂志, 2021, 16(6): 1021-1025. https://www.cnki.com.cn/Article/CJFDTOTAL-SJZX202106011.htm WANG ZQ, PANG GM, WANG KF, et al. Professor Pang Guoming's academic viewpoints of treating diabetes with "harmony"[J]. World J Integr Tradit West Med, 2021, 16(6): 1021-1025. https://www.cnki.com.cn/Article/CJFDTOTAL-SJZX202106011.htm
[8]	黄帝内经[M]. 北京: 中华书局, 2011. The Yellow Emperor' Inner Classic[M]. Beijing: Zhonghua book company, 2011.
[9]	杨泽, 陈佳丽, 汪翔, 等. 清浊相干理论探微[J]. 新中医, 2021, 53(17): 202-205. doi: 10.13457/j.cnki.jncm.2021.17.050 YANG Z, CHEN JL, WANG X, et al. Brief discussion on mutual interference of the clear and the turbid[J]. J New Chin Med, 2021, 53(17): 202-205. doi: 10.13457/j.cnki.jncm.2021.17.050
[10]	梁俊杰, 魏明清, 倪敬年, 等. 田金洲教授升清降浊法治疗帕金森病非运动症状的临床经验[J]. 世界中医药, 2020, 15(16): 2474-2477. doi: 10.3969/j.issn.1673-7202.2020.16.026 LIANG JJ, WEI MQ, NI JN, et al. The clinical experience of raise the clear and direct the turbid downward method of professor Tian Jinzhou in the treatment of non-moter symptom of Parkinson disease[J]. World Chin Med, 2020, 15(16): 2474-2477. doi: 10.3969/j.issn.1673-7202.2020.16.026
[11]	李际强, 王河宝. 升清降浊法的理论基础及临床意义[J]. 江西中医学院学报, 2007, 19(2): 13-14. doi: 10.3969/j.issn.1005-9431.2007.02.007 LI JQ, WANG HB. Theoretical basis and clinical significance of ascending and descending turbidity method[J]. J Jiangxi Univ Tradit Chin Med, 2007, 19(2): 13-14. doi: 10.3969/j.issn.1005-9431.2007.02.007
[12]	张景岳. 张景岳医学全书[M]. 北京: 中国中医药出版社, 1999: 27. ZHANG JY. The Complete Works of Zhang Jingyue[M]. Beijing: China traditional Chinese medicine press, 1999: 27.
[13]	黄元御. 黄元御医学全书[M]. 北京: 中国中医药出版社, 1996: 717. HUANG YY. Huang Yuanyu's Complete Book of Medicine[M]. Beijing: China traditional Chinese medicine press, 1996: 717.
[14]	徐爱华, 万强. 试述脾胃升清降浊理论在临床的运用[J]. 中国中医基础医学杂志, 2010, 16(12): 1179. doi: 10.19945/j.cnki.issn.1006-3250.2010.12.046 XU AH, WAN Q. Discussion on the clinical application of the theory of spleen and stomach ascending clearing and turbidity descending[J]. Chin J Basic Med Tradit Chin Med, 2010, 16(12): 1179. doi: 10.19945/j.cnki.issn.1006-3250.2010.12.046
[15]	李中梓. 医宗必读[M]. 北京: 中国中医药出版社, 2020: 380. LI ZZ. Required Readings from the Medical Ancestors[M]. Bei jing: China traditional Chinese medicine press, 2020: 380.
[16]	章卫平, 史亚男, 陈玉霞. 肠道: 调控糖脂代谢稳态的前哨与枢纽[J]. 国际内分泌代谢杂志, 2021, 41(4): 286-289. doi: 10.3760/cma.j.cn121383-20210513-05023 ZHANG WP, SHI YN, CHEN YX. Intestinal tract: A sentry hub for maintaining glucose and lipid homeostasis[J]. Int J Endocrinol Metab, 2021, 41(4): 286-289. doi: 10.3760/cma.j.cn121383-20210513-05023
[17]	CHÁVEZ-TALAVERA O, TAILLEUX A, LEFEBVRE P, et al. Bile acid control of metabolism and inflammation in obesity, type 2 diabetes, dyslipidemia, and nonalcoholic fatty liver disease[J]. Gastroenterology, 2017, 152(7): 1679-1694. doi: 10.1053/j.gastro.2017.01.055
[18]	杜文晋, 邢华冰, 白秀平. 胆汁酸通过法尼醇受体途径调节糖代谢的研究进展[J]. 中国临床研究, 2022, 35(3): 418-421. doi: 10.13429/j.cnki.cjcr.2022.03.028 DU WJ, XING HB, BAI XP. Research progress of bile acids regulating glucose metabolism through farnesol receptor pathway[J]. Chin J Clin Res, 2022, 35(3): 418-421. doi: 10.13429/j.cnki.cjcr.2022.03.028
[19]	吴晓贤, 王晓柠. 胆汁酸膜受体TGR5在代谢性疾病中作用的研究进展[J]. 中国临床新医学, 2019, 12(1): 97-100. doi: 10.3969/j.issn.1674-3806.2019.01.28 WU XX, WANG XN. Research progress of bile acid receptor TGR5 in metabolic diseases[J]. Chin J New Clin Med, 2019, 12(1): 97-100. doi: 10.3969/j.issn.1674-3806.2019.01.28
[20]	华爽, 吕明慧, 刘倩颖, 等. 糖脂代谢病的发病机制: 多重打击学说[J]. 世界中医药, 2019, 14(3): 638-644. doi: 10.3969/j.issn.1673-7202.2019.03.023 HUA S, LV MH, LIU QY et al. The multiple-hit pathogenesis of glucolipid metabolic disorders[J]. World Chin Med, 2019, 14(3): 638-644. doi: 10.3969/j.issn.1673-7202.2019.03.023
[21]	SMITH GI, SHANKARAN M, YOSHINO M, et al. Insulin resistance drives hepatic de novo lipogenesis in nonalcoholic fatty liver disease[J]. J Clin Invest, 2020, 130(3): 1453-1460. doi: 10.1172/JCI134165
[22]	IIZUKAI K, TAKAO K, YABE D. ChREBP-mediated regulation of lipid metabolism: Involvement of the gut microbiota, liver, and adipose tissue[J]. Front Endocrinol, 2020, 11: 587189. https://www.cnki.com.cn/Article/CJFDTOTAL-HYYW202304008.htm
[23]	GU Y, DUAN S, DING M, et al. Saikosaponin D attenuates metabolic associated fatty liver disease by coordinately tuning PPARα and INSIG/SREBP1c pathway[J]. Phytomedicine, 2022, 103: 154219. doi: 10.1016/j.phymed.2022.154219
[24]	BJORNSTAD P, ECKEL RH. Pathogenesis of lipid disorders in insulin resistance: A brief review[J]. Curr Diab Rep, 2018, 18(12): 127. doi: 10.1007/s11892-018-1101-6
[25]	XIONG P, ZHANG F, LIU F, et al. Metaflammation in glucolipid metabolic disorders: Pathogenesis and treatment[J]. Biomed Pharmacother, 2023, 161: 114545. doi: 10.1016/j.biopha.2023.114545
[26]	CHEN Y, ZHOU J, WANG L. Role and mechanism of gut microbiota in human disease[J]. Front Cell Infect Microbiol, 2021, 11: 625913. doi: 10.3389/fcimb.2021.625913
[27]	JIA X, XU W, ZHANG L, et al. Impact of gut microbiota and microbiota-related metabolites on hyperlipidemia[J]. Front Cell Infect Microbiol, 2021, 11: 634780. doi: 10.3389/fcimb.2021.634780
[28]	JIANG LY, ZHANG HJ, XIAO DS, et al. Farnesoid X receptor (FXR): Structures and ligands[J]. Comput Struct Biotechnol J, 2021, 19: 2148-2159. doi: 10.1016/j.csbj.2021.04.029
[29]	FIORUCCI S, DISTRUTTI E, CARINO A, et al. Bile acids and their receptors in metabolic disorders[J]. Prog Lipid Res, 2021, 82: 101094. doi: 10.1016/j.plipres.2021.101094
[30]	陶俊贤, 冯文焕. 肠道胆汁酸受体与糖脂代谢及肠肝疾病的研究进展[J]. 医学综述, 2017, 23(18): 3565-3569. doi: 10.3969/j.issn.1006-2084.2017.18.007 TAO JX, FENG WH. Research progress of intestinal farnesoid X receptor in glycolipid metabolism and enterohepatic diseases[J]. Med Recapitul, 2017, 23(18): 3565-3569. doi: 10.3969/j.issn.1006-2084.2017.18.007
[31]	SCHUMACHER JD, GUO GL. Pharmacologic modulation of bile acid-FXR-FGF15/FGF19 pathway for the treatment of nonalcoholic steatohepatitis[J]. Handb Exp Pharmacol, 2019, 256: 325-357.
[32]	KIM YC, BYUN S, SEOK S, et al. Small heterodimer partner and fibroblast growth factor 19 inhibit expression of NPC1L1 in mouse intestine and cholesterol absorption[J]. Gastroenterology, 2019, 156(4): 1052-1065. doi: 10.1053/j.gastro.2018.11.061
[33]	FANG S, SUH JM, REILLY SM, et al. Intestinal FXR agonism promotes adipose tissue browning and reduces obesity and insulin resistance[J]. Nat Med, 2015, 21(2): 159-165. doi: 10.1038/nm.3760
[34]	MERTENS KL, KALSBEEK A, SOETERS MR, et al. Bile acid signaling pathways from the enterohepatic circulation to the central nervous system[J]. Front Neurosci, 2017, 11: 617. doi: 10.3389/fnins.2017.00617
[35]	MARUYAMA T, MIYAMOTO Y, NAKAMURA T, et al. Identification of membrane-type receptor for bile acids (M-BAR)[J]. Biochem Biophys Res Commun, 2002, 298(5): 714-719. doi: 10.1016/S0006-291X(02)02550-0
[36]	NAKHI A, WONG HL, WELDY M, et al. Structural modifications that increase gut restriction of bile acid derivatives[J]. RSC Med Chem, 2021, 12(3): 394-405. doi: 10.1039/D0MD00425A
[37]	KEITEL V, REINEHR R, GATSIOS P, et al. The G-protein coupled bile salt receptor TGR5 is expressed in liver sinusoidal endothelial cells[J]. Hepatology, 2007, 45(3): 695-704. doi: 10.1002/hep.21458
[38]	YUSTA B, MATTHEWS D, FLOCK GB, et al. Glucagon-like peptide-2 promotes gallbladder refilling via a TGR5-independent, GLP-2R-dependent pathway[J]. Mol Metab, 2017, 6(6): 503-511. doi: 10.1016/j.molmet.2017.03.006
[39]	SORRENTINO G, PERINO A, YILDIZ E, et al. Bile acids signal via TGR5 to activate intestinal stem cells and epithelial regeneration[J]. Gastroenterology, 2020, 159(3): 956-968, e8. doi: 10.1053/j.gastro.2020.05.067
[40]	VELAZQUEZ-VILLEGAS LA, PERINO A, LEMOS V, et al. TGR5 signalling promotes mitochondrial fission and beige remodelling of white adipose tissue[J]. Nat Commun, 2018, 9(1): 245. doi: 10.1038/s41467-017-02068-0
[41]	KEITEL V, GERTZEN CGW, SCHAFER S, et al. Bile Acids and TGR5 (Gpbar1) Signaling[M]//ROZMAN D, GEBHARDT R. Mammalian Sterols. Cham: Springer, 2020: 81-100.
[42]	YANG YJ, TIAN AF, WU Z, et al. Finger citron extract ameliorates glycolipid metabolism and inflammation by regulating GLP-1 secretion via TGR5 receptors in obese rats[J]. Evid Based Complement Alternat Med, 2021, 2021: 6623379.
[43]	ZHAI HN, LI Z, PENG M, et al. Takeda G protein-coupled receptor 5-mechanistic target of rapamycin complex 1 signaling contributes to the increment of glucagon-like peptide-1 production after roux-en-Y gastric bypass[J]. E Bio Medicine, 2018, 32: 201-214.
[44]	蓝羚升. GLP-1对肥胖合并2型糖尿病患者血糖、血脂、血清胰岛素及糖化血红蛋白的影响[J]. 医药前沿, 2018, 8(29): 79-80. doi: 10.3969/j.issn.2095-1752.2018.29.053 LAN LS. Effects of GLP-1 on blood glucose, lipid, insulin and glycosylated hemoglobin in obese patients with type 2 diabetes mellitus[J]. J Front Med, 2018, 8(29): 79-80. doi: 10.3969/j.issn.2095-1752.2018.29.053
[45]	张安玲, 丁元庆. 基于《内经》探讨卫气的三种状态[J]. 山东中医药大学学报, 2015, 39(4): 309-311. doi: 10.16294/j.cnki.1007-659x.2015.04.004 ZHANG AL, DING YQ. Discussion on three states of protecting qi based on neijing[J]. J Shandong Univ Tradit Chin Med, 2015, 39(4): 309-311. doi: 10.16294/j.cnki.1007-659x.2015.04.004
[46]	POTTHOFF MJ, BONEY-MONTOYA J, CHOI M, et al. FGF15/19 regulates hepatic glucose metabolism by inhibiting the CREB-PGC-1α pathway[J]. Cell Metab, 2011, 13(6): 729-738. doi: 10.1016/j.cmet.2011.03.019
[47]	DE BOER JF, SCHONEWILLE M, BOESJES M, et al. Intestinal farnesoid X receptor controls transintestinal cholesterol excretion in mice[J]. Gastroenterology, 2017, 152(5): 1126-1138, e6. doi: 10.1053/j.gastro.2016.12.037
[48]	刘凯利, 张强, 李军辉, 等. 柴胡人参药对通过调控胆汁酸代谢防治非酒精性脂肪肝的研究[J]. 中华中医药学刊, 2022, 40(3): 101-106, 267. doi: 10.13193/j.issn.1673-7717.2022.03.024 LIU KL, ZHANG Q, LI JH, et al. Drug pair of Chaihu (bupleuri Radix) and Renshen (ginseng Radix et rhizoma) for nonalcoholic fatty liver disease via regulating bile acid metabolism[J]. Chin Arch Tradit Chin Med, 2022, 40(3): 101-106, 267. doi: 10.13193/j.issn.1673-7717.2022.03.024
[49]	肖铁刚, 何道同, 陈珺明, 等. 柴胡人参药对对非酒精性脂肪性肝病大鼠法尼醇X受体和固醇调节元件结合蛋白-1c表达的影响[J]. 中西医结合肝病杂志, 2014, 24(4): 234-238, 257. https://www.cnki.com.cn/Article/CJFDTOTAL-ZXGB201404017.htm XIAO TG, HE DT, CHEN JM, et al. Effects of drug pair of ginseng and Radix bupleuri on expression of FXR, SREBP-1c, and insulin resistance and leptin in rats with nonalcoholic fatty liver disease[J]. Chin J Integr Tradit West Med Liver Dis, 2014, 24(4): 234-238, 257. https://www.cnki.com.cn/Article/CJFDTOTAL-ZXGB201404017.htm
[50]	薛亚楠. 基于FXR/CYP7A1通路探究黄芩黄连药对改善非酒精性脂肪性肝病的作用机制[D]. 南昌: 江西中医药大学, 2021. XUE YN. Exploring the mechanism of Scutellaria-coptis herb couple on non-alcoholic fatty liver disease based on FXR/CYP7A1 pathway[D]. Nanchang: Jiangxi University of Traditional Chinese Medicine, 2021.
[51]	徐路. 基于FXR/FGF15/FGFR4通路研究黄连吴茱萸配伍调控胆汁酸代谢发挥降脂效应的作用机制[D]. 成都: 成都中医药大学, 2020. XU L. Study on the effect of Coptis chinensis and Evodia retaecarpa on regulating bile acid metabolism and lipid-lowering based on the pathway of FXR/FGF15/FGFR4[D]. Chengdu: Chengdu University of TCM, 2020.
[52]	张永, 陈高阳, 张小波, 等. 升清降浊法治疗原发性高脂血症的理论探讨及临证体会[J]. 中药与临床, 2022, 13(4): 54-57. https://www.cnki.com.cn/Article/CJFDTOTAL-LCZY202204007.htm ZHANG Y, CHEN GY, ZHANG XB, et al. Theoretical discussion and clinical experience of Raise the Clear and Direct the Turbid Downward Method for the treatment of primary hyperlipidemia[J]. Pharm Clin Chin Mater Med, 2022, 13(4): 54-57. https://www.cnki.com.cn/Article/CJFDTOTAL-LCZY202204007.htm
[53]	罗雅琪, 陈东辉, 张永, 等. 芩连红曲汤辅治2型糖尿病并高脂血症临床观察[J]. 中医临床研究, 2023, 15(6): 56-59. https://www.cnki.com.cn/Article/CJFDTOTAL-ZYLY202306012.htm LUO YQ, CHEN DH, GUO ZQ, et al. Clinical observation on the Qinlian Hongqu Decoction in the adjuvant treatment of type 2 diabetes mellitus with hyperlipidemia[J]. Clin J Chin Med, 2023, 15(6): 56-59. https://www.cnki.com.cn/Article/CJFDTOTAL-ZYLY202306012.htm
[54]	张小波, 张永, 曾绍谦等. 运用"膏脂"学说治疗非酒精性脂肪性肝病的理论探析及临床运用[J]. 成都中医药大学学报, 2023, 46(1): 10-13, 18. ZHANG XB, ZHANG Y, ZENG SQ, et al. Theoretical analysis and clinical application of non-alcoholic fatty liver disease based on "paste fat" theory[J]. J Chengdu Univ Tradit Chin Med, 2023, 46(1): 10-13, 18.
[55]	郭志清, 张小波, 罗雅琪, 等. 芩连红曲汤对高脂血症大鼠氧化应激和肠道FXR/FGF19信号通路的影响[J]. 中药药理与临床, 2022, 38(6): 20-24. doi: 10.13412/j.cnki.zyyl.20221025.001 GUO ZQ, ZHANG XB, LUO YQ, et al. Effects of Qinlian Hongqu Decoction on oxidative stress and FXR/FGF19 signal pathway in intestine of hyperlipidemia rats[J]. Pharmacol Clin Chin Mater Med, 2022, 38(6): 20-24. doi: 10.13412/j.cnki.zyyl.20221025.001
[56]	ZHANG Y, GUO Z, WANG J, et al. Qinlian hongqu decoction ameliorates hyperlipidemia via the IRE1-α/IKKB-β/NF-κb signaling pathway: Network pharmacology and experimental validation[J]. J Ethnopharmacol, 2023: 116856.
[57]	世界中医药学会联合会代谢病专业委员会. 糖脂代谢病(瘅浊)中西医结合诊疗技术规范[J]. 世界中医药, 2019, 14(3): 771-782. doi: 10.3969/j.issn.1673-7202.2019.03.052 Specialty Committee of Metabolic Diseases of WFCMS. Specification of diagnosis and treatment of glucolipid metabolic disorders(Dan-Zhuo)with integrated Chinese and western medicine[J]. World Chin Med, 2019, 14(3): 771-782. doi: 10.3969/j.issn.1673-7202.2019.03.052
[58]	黄世敬, 王永炎. 论血脂异常与浊毒[J]. 辽宁中医杂志, 2016, 43(1): 65-67. doi: 10.13192/j.issn.1000-1719.2016.01.028 HUANG SJ, WANG YY. Dyslipidemia and turbidity toxin[J]. Liaoning J Tradit Chin Med, 2016, 43(1): 65-67. doi: 10.13192/j.issn.1000-1719.2016.01.028
[59]	李翌萌, 马超, 白长川. 升清降浊法与脂浊[J]. 中国实用医药, 2013, 8(9): 224. doi: 10.3969/j.issn.1673-7555.2013.09.186 LI YM, MA C, BAI CC. Method of clearing and lowering turbidity and lipid turbidity[J]. China Pract Med, 2013, 8(9): 224. doi: 10.3969/j.issn.1673-7555.2013.09.186
[60]	徐凯, 何春霞, 欧爱华. 运用文献计量方法分析升清降浊法的发展及现状[J]. 辽宁中医药大学学报, 2009, 11(5): 263-264. doi: 10.13194/j.jlunivtcm.2009.05.265.xuk.085 XU K, HE CX, OU AH. Analysis the application status and trends of ascending lucidity and descending turbidity with bibliometric methods[J]. J Liaoning Univ Tradit Chin Med, 2009, 11(5): 263-264. doi: 10.13194/j.jlunivtcm.2009.05.265.xuk.085
[61]	陈荣, 欧阳琦. 试论"清浊"相干[J]. 云南中医学院学报, 1983, 6(3): 1-3. https://www.cnki.com.cn/Article/CJFDTOTAL-YNZY198303000.htm CHEN R, OUYANG Q. Exploring the theory of Disorder between "Qing and Zhuo"[J]. J Yunnan Coll Tradit Chin, 1983, 6(3): 1-3. https://www.cnki.com.cn/Article/CJFDTOTAL-YNZY198303000.htm
[62]	吴倩. 半夏泻心汤治疗2型糖尿病脾胃不和证临床疗效观察[D]. 北京: 北京中医药大学, 2021. WU Q. Clinical observation of Banxia Xiexin Decoction in treating type 2 diabetes mellitus syndrome of spleen-stomach disharmony[D]. Beijing: Beijing University of Chinese Medicine, 2021.
[63]	绽永华, 王学红, 王芳. 半夏泻心汤加减对非酒精性脂肪肝的临床疗效及对胰岛素抵抗的调节效果观察[J]. 中国实验方剂学杂志, 2021, 27(3): 117-122. doi: 10.13422/j.cnki.syfjx.20200833 ZHAN YH, WANG XH, WANG F. Regulatory effect of modifiedBanxia Xiexintang on insulin resistance of patients with nonalcoholic fatty liver[J]. Chin J Exp Tradit Med Formulae, 2021, 27(3): 117-122. doi: 10.13422/j.cnki.syfjx.20200833
[64]	沈涛. 黄连吴茱萸组方对实验性高脂模型小鼠的降脂实验研究[J]. 成都中医药大学学报, 2007, 30(1): 18-19. doi: 10.3969/j.issn.1004-0668.2007.01.009 SHEN T. Experimental study of Huanglian Zhuyu prescription on lowering blood lipid in experimental hyperlipidemia model mice[J]. J Chengdu Univ Tradit Chin Med, 2007, 30(1): 18-19. doi: 10.3969/j.issn.1004-0668.2007.01.009